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Objective: Erosive osteoarthritis of the hand (EHOA) is thought to be an aggressive variant of hand
osteoarthritis (HOA) characterised by prominent local inﬂammation and radiographic aspects of bone
erosions in interphalangeal (IP) joints. However, rare studies have until now investigated the value of
biomarkers in these patients. Thus, we determined Coll2-1, a marker of type II collagen denaturation, its
nitrated form (Coll2-1NO2) and myeloperoxidase (MPO) levels in serum of patients with EHOA vs non-
EHOA and subsequently evaluated their relationships with disease indices of severity and activity.
Methods: Coll2-1, Coll2-1NO2 and MPO were measured using speciﬁc immunoassays in 82 patients, 57
with EHOA, all females, median age 59 (41e74 yrs) and 20 with non-EHOA, all females, median age 55
(43e73 yrs), fulﬁlling the American College of Rheumatology (ACR) criteria for hand OA. EHOA was
characterized by the presence of at least one central bone erosion on radiograph in the IP joints. Patients
were also evaluated for disease duration, number of affected (swollen and painful or tender) joints,
radiographic score (RS) by Kallman scale and high sensitivity C-reactive protein (hsCRP).
Results: Serum levels of MPO were higher in EHOA (230.0 152.1 ng/ml) than in non-EHOA
(160.2 111.5 ng/ml, P¼ 0.037). Coll2-1NO2 levels trended towards an elevation in EHOA compared
non-EHOA (0.40 0.86 vs 0.22 0.14 nmol/l, P¼ 0.06), while Coll2-1 levels were not different. Corre-
lations were found for disease duration and both MPO (R2¼ 0.48, P¼ 0.001) and Coll2-1NO2 (R2¼ 0.73,
P¼ 0.01) after the splitting of the population in subgroups according to a cut off value above the 50th
percentile. A correlation was found between hsCRP and MPO (R2¼ 0.57, P¼ 0.01).
Conclusions: This study clearly demonstrates an elevation of some serum biomarkers in EHOA, in
comparison with non-EHOA. In particular, MPO, hsCRP and the ratio Coll2-1NO2/Coll2-1 discriminated
the two subsets of hand osteoarthritis (HOA), and a trend was also observed for Coll2-1NO2. These data
suggest that these biomarkers could be helpful for the diagnosis of EHOA.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Erosive hand osteoarthritis (EHOA) targets interphalangeal
(IP) joints and is characterized by an abrupt onset, a severe pain
and functional impairment, inﬂammatory symptoms and signs,
including stiffness, soft tissue swelling, erythema, paraesthesiae,to: Y. Henrotin, Bone and
of Pathology, Level þ5, CHU
Fax: 32-4-3664734.
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s Research Society International. Pand worse outcomes than non-erosive hand osteoarthritis (OA)
(non-EHOA)1e8. Diagnosis is uniquely based on the radiographic
aspects of subchondral articular surface erosion, which may prog-
ress to marked cartilage and bone attrition, joint instability and
bone ankylosis, associated with the classical features of OA1,4,5,9e11.
The recent EULAR recommendations and clinical trials suggest that
EHOA should be considered as a subset of HOA5,9,10, although some
authors have questioned this interpretation, suggesting that EHOA
merely represents a phase in the evolution of classical HOA12. In the
absence of a well deﬁned phenotype, the analysis of some
biochemical markers may contribute to better characterize EHOA.
To the best of our knowledge, only few studies have considered this
aspect. Higher serum levels of high sensitivity C-reactive protein
(hsCRP) in patients with EHOA in comparison with non-EHOA haveublished by Elsevier Ltd. All rights reserved.
Table I
Main characteristics of patients with EHOA and with non-EHOA
EHOA Non-EHOA P
Women, no. 57 20 e
Age: years, median, range 59 (41e74) 58 (43e73) 0.37
Disease duration: years, M SD 8.9 6.6 4.5 3.6 0.048
NCAJ 12.0 5.0 8.3 4.5 0.005
RS 71.1 28.5 29.6 15.4 0.009
Number of erosions 4.5 2.6 e e
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another study, patients with EHOA showed increased levels of
soluble receptor of interleukin-2 (sIL-2R) a marker of lymphocyte
activity15. The C-telopeptide of type II collagen (CTX II) was found to
be increased in serum and urine of EHOA in comparisonwith nodal
non-EHOA16. CTX I was also found elevated in the urine of EHOA
compared to non-EHOA17,18. Finally, serum levels of hyaluronic acid
(HA), considered asmarker of synovitis, were signiﬁcantly higher in
EHOA in comparison with non-EHOA19.
Type II collagen is the major structural protein in cartilage,
making up approximately 50% of the extracellular cartilage matrix.
Type II collagen-derived fragments have been extensively investi-
gated as potential markers of cartilage remodelling in OA and
rheumatoid arthritis (RA). No differences in serum levels of type II
collagen degradation biomarkers were observed between patients
with EHOA and non-EHOA in a study conducted in Canada some
years ago20. Recently, Henrotin and collaborators have developed
two new immunoassays for the measurement of type II collagen-
derived fragments. One assay was speciﬁc for the sequence
108HRGYPGLDG116 derived from the triple helical region of type II
collagen (Coll2-1) and the other for its nitrated form (Coll2-1NO2).
The development of a speciﬁc immunoassay for the measurement
of nitrated type II collagen fragments in biological ﬂuids seems
relevant to study the impact of the oxidative damage in cartilage
pathophysiology. These assays have been validated in serum of
healthy subjects and of patients with OA and RA21. Plasma myelo-
peroxidase (MPO) is the predominant protein present in primary
granules of circulating polymorphonuclear cells. It is a member of
the human peroxidase family, heme-containing enzymes that play
a role in host defence against infection, hormone synthesis, and in
the pathogenesis of some diseases. MPO is the major enzymatic
source of leukocyte-generated oxidants, released by activated
neutrophils and used as a marker of leukocyte recruitment and
function and subsequent inﬂammation. Moreover, MPO concen-
tration is related to inﬂammatory activity and could play an
important role in the maintenance of oxidative stress in RA22. MPO
was found to be elevated in patients with knee and hip OA candi-
dates for prosthesis23.
The aim of this study was to determine Coll2-1, Coll2-1NO2 and
MPO levels in serum of patients with EHOA and compare thesewith
the levels in non-EHOA. Furthermore, we investigated the possible
relationships between these biomarkers and the clinical and
radiological indices of disease severity and activity.
Methods
Patients
Seventy seven consecutive patients, 57 with EHOA (57 women,
median age 59 yrs, range 41e74 yrs) and 20 with non-EHOA
(20 women, median age 58 yrs, range 43e73 yrs), fulﬁlling Amer-
ican College of Rheumatology (ACR) criteria for HOA24 were
included in the study. EHOA was deﬁned as hand OA with at least
one central bone erosion in IP joints, while patients with erosions in
metacarpophalangeal joints and/or thumb base joint were
excluded. We also excluded patients with other known arthropa-
thies, personal and/or familial history of psoriasis and with active
bone scan in lower limb and in sacroiliac. Patients were also eval-
uated for disease duration in years, number of clinically active
(swollen and painful or tender) joints (NCAJ), radiographic score
(RS) by Kallman scale25 (Table I). The radiological assessment was
performed by one single experimented reader on all joints at the
exception of the thumb base joints according a previously
described protocol13. The intra-observed precision was less than
10%. Non-EHOA patients were selected out of 30 consecutivepatients referred to our clinical centre with active disease but
without radiological signs of bone erosion in IP joints. After an
informed consent, these patients were submitted to bone scan and
those with active bone scan in lower limbs and in sacroiliac joints,
were subsequently excluded. Out of the 30 consecutive patients, 10
were excluded for positive bone scan. Non-EHOA groupwas limited
to 20 patients for ethical reasons.
Immunoassays
Coll2-1 and Coll2-1NO2 concentrations were measured by
two new competitive and speciﬁc immunoassays (Enzyme-linked
immunosorbent assay (ELISA))26. The Coll2-1 immunoassay only
measured the amino acid sequence 108HRGYPGLDG116 in its linear
form while the Coll2-1NO2 immunoassay quantiﬁed with a high
speciﬁcity and afﬁnity the nitrated amino acids sequence. Coll2-
1NO2/Coll2-1 is the ratio of nitrated Coll2-1 which reﬂects the
oxidative stress occurring in cartilage. The limits of detection were
17 nM for Coll2-1 immunoassay and 25 pM for Coll2-1NO2
immunoassay. The intra- and inter-assays CVs were lower than
10% and the dilution curves were parallel to the standard curve for
both assays. The analytical recoveries were in mean 104.7% and
121.9% for Coll2-1 and Coll2-1NO2 assays, respectively.
MPO was determined by a commercially available ELISA kit
(ELIZEN MPO, Zentech SA, Liège, Belgium).
hsCRP values were assessed by a highly sensitive immunone-
phelometric method (DADE Behring, Milan, Italy) on a BN II
Analyzer. The lower limit of detection was 0.175 mg/l (analytical
sensitivity 0.04 mg/l).
Statistical analysis
Quantitative variables were summarized as mean (M) stan-
dard deviation (SD) for those showing normal distribution and by
median and range for non-normal ones. Analysis of variance, t test
and Wilcoxon for unpaired samples were used to compare values
among groups and Chi square test for categorical distributions. For
differences statistically signiﬁcant at the univariate analysis, age
adjustment was performed with analysis of covariance (ANCOVA)
applying general linear models entering age and EHOA type as
independent variables and MPO or hsCRP as dependent ones.
For the analysis of the correlation between biomarkers and
disease duration, the population was divided in subgroups accord-
ing to cut off values above the 50th percentile, namely
MPO¼ 214.0 ng/ml and Coll2-1NO2¼ 0.30 nmol/l. All statistical
analyses were performed using statistical package for the social
sciences (SPSS) (SPSS, vers 16 Inc Illinois, USA).
This protocol was approved by the ethical committee of the
University of Padova (1686P/13.10.08).
Results
Main characteristics of the patients were reported in Table I.
EHOA and non-EHOA populations were statistically different
for: NCAJ (12.2 5.2 vs 8.3 4.5 respectively, P¼ 0.005), RS
Fig. 1. Correlation between hsCRP and MPO.
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erosions (4.5 2.6 vs 0.0). Serum levels of MPO were higher in
patients with EHOA (230.3152.1 ng/ml) than in those with non-
EHOA (160.2111.5 ng/ml, respectively; P¼ 0.037). hsCRP was
also signiﬁcantly higher in EHOA than in non-EHOA (4.7 3.3 vs
2.11.1; P¼ 0.001). Coll2-1NO2 levels trended towards an eleva-
tion in EHOA patients compared with non-EHOA (0.40 0.8 nM vs
0.19 0.14 nmol/l, P¼ 0.06), while Coll2-1 levels were not signiﬁ-
cantly modiﬁed (115.2 65.4 vs 114.9 55.0 nmol/l, P¼ 0.1).
Median and range were shown in Table II. The ratio Coll2-1NO2/
Coll2-1 was higher in EHOA than in non-EHOA patients, but
difference was not signiﬁcant (P¼ 0.07). When the EHOA pop-
ulation was divided in subgroups according to a cut off value above
the 50th percentile, correlations were found for disease duration
and both Coll2-1NO2 (R2¼ 0.73, P¼ 0.01) and MPO (R2¼ 0.48,
P¼ 0.001). A correlation was found between hsCRP and MPO
(R2¼ 0.57, P¼ 0.01) (Fig. 1), but not between hsCRP and Coll2-
1NO2/Coll2-1 ratio or Coll2-1NO2. No correlations were found
between each of these biomarkers and NCAJ or RS.Discussion
Our study demonstrates that serum levels of MPO and the ratio
Coll2-1NO2/Coll2-1 are higher in EHOA than in non-EHOA.
Furthermore, although not signiﬁcantly, a trend was also observed
for increased values of Coll2-1NO2 in EHOA compared to non-EHOA.
In contrast, Coll2-1 levels were not signiﬁcantly different. These
results contribute to a better understanding of pathophysiological
changes associated with this subset of HOA, still in search of a more
precise characterization.
Coll2-1NO2 is the nitrated form of collagen-derived fragments
and probably reﬂects the impact of the oxidative damage in carti-
lage pathophysiology. During local inﬂammatory reaction, reactive
oxygen and nitrogen species are produced by macrophages,
neutrophils but also by chondrocytes in response to cytokines or
products of tissue degradation. Reactive oxygen and nitrogen
species, mostly peroxynitrite (ONOO) and HOCl/OCl produced
by MPO, are involved in type II collagen breakdown and
nitration27e29.
The increased levels of MPO and Coll2-1NO2 suggest that EHOA
is associated with an oxidative degradation of joint. Anyway, there
were only few studies demonstrating some changes in OA
biomarkers13,16e19.
In this context, serum levels of hsCRP were measured in
a previously published case control study examining 67 patients
with EHOA and 31 patients with non-EHOA13. hsCRP levels were
higher in the EHOA group and the correlations between hsCRP
level, radiographic severity scores and number of joints involved
supported hsCRP as an indicator of disease activity. However, the
results of this study were in contrast with those previously repor-
ted by Olejarova et al., who found in EHOA higher values for the
erythrocyte sedimentation rate but lower values for serum CRP14.
The discrepancies between these two studies may be due to several
reasons, including differences in the number of EHOA patients
examined, 67 vs 28 in the second study, and in the method for CRPTable II
Serum levels (median, range) of biomarkers analysed in patients with EHOA and non-EH
Age matched non-OA subject (n¼ 77)
Coll2-1 nmol/l 107.79 (28.77e296.94)
Coll2-1NO2 nmol/l 0.26 (0.05e0.71)
Coll2-1NO2/Coll2-1 ratio e
MPO ng/ml 57.7 (<0e216.74)
hsCRP mg/l edetection. However, in the present study, our previous data on
higher hsCRP in EHOA have been conﬁrmed. Furthermore, we
found a correlation between hsCRP and MPO, which suggests the
role of inﬂammation in EHOA6.
As regards as the value of other biomarkers in EHOA, in a very
recent study, Filková et al. found that serum levels of HA, consid-
ered as a marker of synovitis, were signiﬁcantly higher in 55
women with EHOA in comparison with non-EHOA19. Furthermore,
HA levels correlated with the number of hand joints showing
deviations and deformities and, when adjusted for age and disease
duration, with radiographs at baseline and after 2 yrs in all patients
with HOA. These results indicate that HA may be a marker of
synovitis and of radiographic progression in EHOA. The presence of
synovitis in patients with HOA, both EHOA and non-EHOA, has been
matter of discussion for many years. In some studies performed in
EHOA bymean of a power-Doppler ultrasonography, the ﬁndings of
synovial membrane thickening and increase vascularity indicative
of active synovitis were found in the vast majority of patients with
EHOA30e33. The percentages of distal IPs and proximal IPs with
active synovitis on the right and left hands were 50% and 44.3% and
14.8% and 21.6%, respectively. These ﬁndings are thus consistent
with the term “inﬂammatory form of OA” that has been attributed
to this subset of HOA6. In this context, the inﬂammatory signs more
expressed in our patients with EHOA than in those with non-EHOA
seem in agreement with the increased value of serum MPO. Obvi-
ously, further studies are necessary to better understand the
process underlying the high production of MPO in EHOA.
With respect to the other biomarkers analysed in this study, no
difference was found in Coll2-1 values between EHOA and non-
EHOA. However, due to the limited cartilage articular surface of
hand joints, which is further reduced with the disease progression,
it is possible that the amount of Coll2-1 released from hand joints
was not enough to inﬂuence the systemic Coll2-1 level. On the
other hand, our results corroborate those of a previous study per-
formed with other type II collagen epitopes20. No differences in
serum levels of type II cartilage biomarkers were observed between
30 patients with EHOA and 29 patients with non-EHOA. MPO,OA
EHOA (n¼ 57) Non-EHOA (n¼ 20) P
108.0 (33.0e367.5) 106.5 (34.5e245.5) 0.15
0.26 (0.03e6.3) 0.19 (0.025e0.59) 0.06
0.0022 (0.0005e0.02) 0.0016 (0.0007e0.003) 0.07
186.6 (33.3e678.4) 119.8 (35.9e450.0) 0.03
4.7 (2.4e6.9) 2.1 (0.5e4.9) 0.001
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the radiological and clinical severity of the disease. This indicates
that these are biomarkers of the burden of EHOA. Furthermore,
Coll2-1NO2 but not Coll2-1 was signiﬁcantly correlated with CRP in
serum of patients with EHOA, suggesting that Coll2-1NO2 could be
a promising speciﬁc marker of arthritic HOA disease activity.
This study suffers of major limitations including the small
number of non-EHOA patients. These limitations were mainly due
to the use of bone scan as a selection criterion. Subsequently, we
were obliged for ethical raisons to limit the number of non-EHOA
participants submitted to bone scan. Although this is a major
caveat of the study, it allows us to carefully exclude patients with
subclinical involvement of lower limbs OA, which may have a
relevant inﬂuence in the biomarker evaluation. Ideally, to discrim-
inate non-EHOA and EHOA with an 80% power for the assumed
effect, 45 non-EHOA was required. Another limitation is the
heterogeneity of the distribution of the biochemical factors which
deviate from normality. This can be explained by the heterogeneity
in the activity, the extent and the severity of the disease.
In conclusion, this study gives insight in a better understanding
of EHOA, both for the pathogenesis and for clinical characterization
of EHOA.
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